The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Exploring FOLFIRI and checkpoint inhibitors in gastric adenocarcinoma
David Tougeron, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses the findings from the PRODIGE 59-FFCD 1707-DURIGAST trial (NCT03959293), which evaluates the efficacy of combining FOLFIRI with tremelimumab (anti-CTLA-4) and durvalamab (anti-PD-1) as second-line treatment for gastric adenocarcinoma. The trial has demonstrated a favorable response rate among patients receiving this combination therapy. Beyond biomarkers such as PD-L1 expression and combined positive scores (CPS), researchers are exploring novel predictive and prognostic biomarkers such as tumor mutation burden (TMB). This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
